

The Effects of Vitamin D₃ on Brain Development and Autism

Ilknur Ibili Ucuz¹, Onur Burak Dursun², Nazan Aydin³

ABSTRACT:

The effects of vitamin D₃ on brain development and autism

Vitamin D₃ has long been known to affect the skeletal system and mineral metabolism. In recent years, there has been an increasing interest in the effects of vitamin D₃ on different systems. The relation of vitamin D₃ with brain development and autism is an intensely researched area in this context. The aim of this paper is to review the current evidence on the effects of vitamin D₃ on brain development and autism and to provide insights for future scientific studies.

Vitamin D₃ has been shown to have direct effects on neural development, neural cell proliferation and apoptosis. Moreover, this vitamin also has effects on the immune system, inflammation processes, and antioxidation, which in turn are known to have effects on brain development. Current evidence suggests that vitamin D₃ has a critical effect on brain development and that vitamin D₃ deficiency might have detrimental effects on mental development.

Similarly, vitamin D₃ deficiency and autism show many similarities in their etiopathogenesis. However, clinical studies showing the link between vitamin D₃, brain development and autism are limited. The data obtained in this area are based on animal studies, and current data do not seem to be sufficient to allow for direct conclusions.

Keywords: vitamin D₃, autism, brain development

Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(3):302-11



¹M.D., ²Assist. Prof., Ataturk University, School of Medicine, Department of Child and Adolescent Psychiatry, Erzurum - Turkey
³Prof., Bakirkoy Mental Health and Neurological Diseases Training and Research Hospital, Department of Psychiatry, Istanbul - Turkey

Corresponding author:

Assist. Prof. Onur Burak Dursun
Ataturk University, School of Medicine,
Department of Child and Adolescent
Psychiatry, Erzurum - Turkey

E-mail address:

obur.dursun@atauni.edu.tr

Date of submission:

April 30, 2014

Date of acceptance:

October 24, 2014

Declaration of interest:

I.I.U., O.B.D., N.A.: The authors reported no conflict of interest related to this article.

INTRODUCTION

Vitamin D₃ has long been known to have effects on bone and mineral metabolism, and in the Eastern cities of Turkey, vitamin D₃ deficiency due to the long winter season has commonly been observed to lead to health problems¹. Recently, vitamin D₃ has also been demonstrated to have pro-differential, anti-proliferative, pro-apoptotic and anti-inflammatory effects, besides affecting the skeletal system. The number of studies on the effects of vitamin D₃ on different systems has increased dramatically¹. Brain development and psychiatric disorders are among the most

commonly researched areas with respect to the effects of vitamin D₃¹⁻⁶.

The purpose of this review is to examine the effects of vitamin D₃ on brain development and autism, and to provide insights for future scientific studies looking into neurobiological hypotheses that can explain this relationship.

Vitamin D₃ and the Brain

Effects of vitamin D₃ on the brain have been gaining importance in recent years. In earlier studies, it was revealed that vitamin D₃ metabolites can pass the blood-brain barrier, and

the presence of vitamin D₃ was identified in human cerebrospinal fluid^{7,8}. Subsequent studies have been conducted to determine whether vitamin D₃ synthesis and metabolism occur in the brain. In related studies, it has been determined that, besides the 25-hydroxyvitamin D₃-1 alpha hydroxylase enzyme playing a role in vitamin synthesis, cytochrome P450 enzymes such as CYP24A1 (24-alpha hydroxylase), which take part in vitamin D₃ inactivation, are also present in brain cells^{9,10}.

Another area of research on vitamin D₃ and the brain is the work carried out on VDRs (vitamin D₃ receptors). Johnson and his team revealed the presence of VDRs in rat fetus brain dorsal stem ganglion cells¹¹, and in subsequent studies, it was proven that VDRs are present in both the neuronal and glial cells of human and rodent brains¹⁰. While these data do not provide proof of a causal relationship, they suggest that vitamin D₃ might have an effect on cell apoptosis and the cell cycle in the brain.

The mechanisms of actions of vitamin D₃ on the brain and its development is another research topic. Studies conducted in this area have focused on many different mechanisms, which will be explained in the subsequent section.

1. Direct Effects of Vitamin D₃ on Neural Development

Numerous studies demonstrate that vitamin D₃ also plays a role in cellular differentiation. In a study that examined the effects of vitamin D₃ on mitosis and axon development and used nerve growth factor (NGF) production as an alternative mediator, Brown et al. confirmed that vitamin D₃ added to their hippocampal cell culture caused a decrease in the number of the proliferative cells and led to an increase in the development of neurites⁶. In a study on the effects of maternal vitamin D₃ deficiency on cell reproduction and apoptosis in the rat embryo cortex at different developmental stages, it was revealed that vitamin D₃ has a regulatory role at both cellular and molecular levels. After comparison with the control

group, it was confirmed that apoptosis decreases more significantly at birth and, irrespective of developmental stage, mitosis increases in newborns and embryos born to mothers with vitamin D₃ deficiency³. In rats born to mothers with vitamin D₃ deficiency, it has been found that the brain cortex is longer, the lateral ventricles are widened, and there is more cell reproduction in the brain tissue where the cortex is thinner^{10,12}. Furthermore, a decrease in the NGF, glial cell line-derived neurotrophic factor (GDNF) levels and expression of neurotrophin receptor p75NTR is also reported in vitamin D₃-deficient rats¹². In support of these results, Cui et al. found that vitamin D₃ regulates cellular proliferation in the developing brain¹³. All of this research suggests that vitamin D₃ may have a direct effect on neural expansion, differentiation, and cell death in the human brain.

Neurotrophins are also thought to be related to vitamin D₃ and neuronal development. It has been determined that vitamin D₃ has an indirect effect on neuronal development through a change in neurotrophic factor production in glial cells¹⁴. In a study by Neveu et al., it was demonstrated that supplementing primary cultures of astrocytes with vitamin D₃ decreases the synthesis of neurotrophin-4 (NT-4) mRNA and increases NGF and neurotrophin-3 (NT-3) mRNA levels¹⁵. Brown et al. found that there is an increase in neurite outgrowth following vitamin D₃ supplementation to rat hippocampal cell culture and an increase in the NGF levels in proportion to the decrease in mitotic division rates⁶. Saporito et al. also determined that NGF expression increases in the hippocampus of adult rats after the application of vitamin D₃¹⁶. Nerve growth factor has been found to have an effect on the growth and survival of many neurons in the brain, including cholinergic neurons of the basal forebrain¹⁷, besides having a role in neuronal plasticity, neuronal membrane excitability, and the development and regulation of immune cells¹⁸. Reduced serum NGF levels have been observed in psychiatric disorders such as schizophrenia¹⁸. From the background of these studies, vitamin D₃ can be thought to regulate the life cycle of neurons.

Glial cell-derived neurotrophic factor, also known as GDNF is also a crucial component in the development of dopaminergic and noradrenergic systems^{19,20}. It has been thought that GDNF plays a role in heroin dependence²¹. Naveilhan et al. have shown that supplementing C6 glioma cells with 1,25(OH)₂D increases the synthesis of GDNF mRNA²². There are cases indicating that GDNF might play a role in various behavioral mechanism models that include sensorimotor behaviors and schizophrenia^{23,24}.

Moreover, in animal research, developmental vitamin D₃ deficiency has been found to have an effect on long-term memory and learning disorders²⁵. Results of another study with rats born to mothers with a temporary vitamin D₃ deficiency compared to a control group indicated that there were structural changes in the brain, including a decrease in NGF levels and gene expression of some factors that affect the neuronal structure of the brain. These results demonstrate that temporary vitamin D₃ deficiency in early developmental stages causes permanent changes in the adult brain. These findings are important for community health, in particular with regard to D₃ hypovitaminosis in women of fertility age⁴. In a study carried out in Turkey, no significant differences in NGF levels was found in control groups compared to subjects with low vitamin D₃ levels. However, a significant negative correlation was found between vitamin D₃ and NGF levels²⁶.

2. The Role of Vitamin D₃ in Neuroprotection

In the cell, there is a balance between the reactive oxygen types produced during aerobic metabolism and the anti-oxidant protective mechanisms that play a role in free radical inactivation. There are two protective mechanisms—enzymatic and non-enzymatic. Superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and ceruloplasmin are enzymatic protective mechanisms. Glutathione and its precursors—folate, vitamin B₆ and vitamins A, C and E—are non-enzymatic protectors²⁷. It has been found that vitamin D₃

increases glutathione levels, raising the level and activity of the gamma-glutamyl enzyme responsible for glutathione production in physiologic concentrations²⁸. In a study by Wang et al., vitamin D₃ was shown to decrease ischemia-based brain damage in the adult rat cortex²⁹. Further, vitamin D₃ has been found to protect the brain against the cytotoxicity induced by the excitatory neurotransmitter glutamate and dopaminergic toxins^{30,31}.

Intracellular free calcium imbalance is neurotoxic in both embryonic and adult brain tissue⁹. Vitamin D₃ is considered to increase the expression of proteins that connect intracellular calcium, thus protecting neurons from calcium-mediated toxicity^{9,32}. Brewer et al. found that the active form of vitamin D₃ regulates L-type voltage-sensitive calcium channels in embryonic cortical neurons^{9,33}. These results support the fact that vitamin D₃ has a protective effect in that it regulates the cellular intake of calcium. However, the evidence for the existence of this mechanism in embryonic brain cells is weak.

3. The Effects of Vitamin D₃ on Dopamine

Limited data show that vitamin D₃ has a neuroprotective effect on the neurons constituting the brain's dopaminergic system¹⁴. In a study by Cass et al., rats were repeatedly exposed to methamphetamine in neurotoxic doses, which decreased the dopamine and serotonin levels in the striatum and nucleus accumbens. Upon introduction of vitamin D₃, these levels improved significantly, suggesting that vitamin D₃ has a protective effect on the dopaminergic system³⁴.

Another effect of vitamin D₃ in the dopaminergic pathways is the increase in dopamine synthesis. A study on adrenal medulla tissues of rats also demonstrated that vitamin D₃ increases dopamine through tyrosine hydroxylase, one of the enzymes involved in dopamine synthesis³⁵. In a study in which the post-mitotic factors crucial for dopaminergic neuron development were examined, it was found that there was a decrease in the Nurr1 and p57kip2

phenotype in the mesencephalic embryonic brains of rats with vitamin D₃ deprivation^{9,36}. In another study that measured dopamine levels in the forebrain of newborn rats with vitamin D₃ deprivation, it was demonstrated that there was a reduction in the conversion of dihydroxyphenylacetic acid (DOPAC) to homovanillic acid (HVA), and that vitamin D₃ deficiency affected dopamine turnover in the developmental process even when there was no change in dopamine levels³⁷. In addition, rats born to mothers with vitamin D₃ deficiency have been shown to have symptoms of hyperactivity³⁸.

4. Anti-Inflammatory Effects of Vitamin D₃

The anti-inflammatory effect of vitamin D₃ on the developing brain is another area of research. Vitamin D₃ is an important immune modulator³⁹. Garcion et al. revealed that vitamin D₃ suppressed induced nitric oxide synthase (iNOS) expression and caused a six times increase in the number of macrophages and a decrease in the number of apoptotic cells at the lesion site during inflammation of the brain induced by lipopolysaccharides⁴⁰. In another study, inflammatory mechanisms simulated in an experimental autoimmune encephalitis model were found to decrease with vitamin D₃ levels⁴¹. Furthermore, vitamin D₃ metabolites have been found to suppress the stimulant effect of epidermal growth factor on vascular smooth muscle cells and thus inflammation⁴². In a study conducted by Tiims et al., vitamin D₃ deficiency was found to be related to an increase of circulating matrix metalloproteinase 2 (MMP2) and C-reactive protein (CRP) which could be reversed with vitamin D₃ support⁴³. This study demonstrated that there was an inverse relationship between C-reactive protein, an effective factor in inflammation, and vitamin D₃⁴³. It has also been found that NF- κ B activity, one of the factors in inflammation, is suppressed by vitamin D₃⁴⁴.

Although several mechanisms have been proposed, the hypothesis that vitamin D₃ achieves this effect through T-cell function has gained the

most recognition⁴⁵. Macrophages and dendritic cells have VDR ligands, 1-alpha hydroxylase enzyme is up-regulated by active macrophages, and activated macrophages are able to synthesize and secrete 1,25(OH)2D3. These findings provide further evidence of the role of vitamin D₃ in reducing inflammation^{46,47} and support the role of vitamin D₃ in anti-inflammatory processes; however, more studies are needed to determine how vitamin D₃ affects brain functions related to psychiatric disorders and behavioral processes.

All these findings support the hypotheses that vitamin D₃ levels have a critical effect on brain development and that vitamin D₃ deficiency might have detrimental effects on mental development and may cause behavioral problems. Possible mechanisms linked to the effects of vitamin D₃ on brain development were summarized in Table 1.

Pathophysiology of Autism Spectrum Disorder (ASD) and Its Relationship with Vitamin D₃

Vitamin D₃ deficiency and autism show many similarities in their etiopathogenesis. Findings on autism indicate that this condition is more common in urban areas, in climates with less sunlight, at higher elevations and in areas with high air pollution, all of which coincide with the etiology of vitamin D₃ deficiency⁴⁸⁻⁵⁰. In the few studies where plasma vitamin D₃ levels of autistic children were compared with a control group, contradictory results were obtained⁵¹⁻⁵³. In a study by Meguid et al., it was determined that children with autism spectrum disorder (ASD) had lower serum calcidiol and calcitriol levels compared to the healthy control group⁵¹. On the other hand, there is also research that shows similar or lower vitamin D₃ levels in children with ASD compared to control groups^{52,53}. A study carried out in Turkey compared children with ASD and developmental delay, and children with only developmental delay (DD), and no difference in their basal vitamin D₃ levels was observed. In the next phase of that study, vitamin D₃ replacement was provided with special training for the cases of vitamin D₃

Table 1. The Effects of Vitamin D on Brain Development

Potential Effect	Effect Mechanism	References
Neurotrophic effect (factors that affect neuronal differentiation, maturation and growth)	NGF mRNA increased NT-3 mRNA increased NT-4 mRNA down regulated GDNF mRNA increased	Neveu et al., 1994a; Neveu et al., 1994a; Neveu et al., 1994a; Naveilhan et al., 1996
Neuroprotective effect	Increase of glutathione through the increase of gamma-glutamyl transpeptidase	Garcion et al., 1999
Antioxidant effect	Neuronal protection against neurotoxicity induced by oxygen free radicals such as hydrogen peroxide Decrease in iNOS	Ibi et al., 2001 Garcion et al., 1997
Intracellular calcium regulation	Down-regulation of voltage-sensitive Ca ²⁺ paths Increase in intracellular calcium-linking proteins	Brewer et al., 2001 Alexianu et al., 1998
Effect on dopaminergic system	Neuroprotective effect on dopaminergic paths	Cass et al., 2006; Puchacz et al., 1996
Effect on neurotransmission and neuroplasticity	Morphologic changes in the brain in developmental vitamin D deficiency Neurite outgrowth increases Changes in apoptosis, mitosis and neurogenesis in vitamin D deficiency	Féron et al., 2005; Eyles et al., 2003 Brown et al., 2003 Ko et al., 2004; Féron et al., 2005; Brown et al., 2003
Anti-inflammatory effect	Suppressed inflammatory response	Garcion et al., 1998; Nataf et al., 1996; Carthy et al., 1989; Cantorna et al., 2005; Garcion et al., 1997;

deficiency. The results showed that in both groups, vitamin D₃ growth values were normal for children who received replacement and significantly better than the values for the children who did not receive treatment²⁶. Molecular systems in which vitamin D₃ plays a role and which have also been suspected in ASD pathophysiology will be discussed in subsequent sections.

A. Neurogenesis and Neurotrophic Factors

Congruencies between the biological mechanisms thought to take part in ASD and the mechanisms in which vitamin D₃ plays a role are striking (Table 2). There are overlaps between neural growth steps in which vitamin D₃ takes part and the pathways implicated in the development of autism spectrum disorders^{9,54,55}. Halicka et al. have argued that vitamin D₃ plays a role in decreasing DNA damage by acting as an agent in DNA repair⁵⁴. Genetic mutations resulting from DNA damage are also implicated in the pathogenesis of

ASD⁵⁵. In a study in rats conducted by Taniura et al., vitamin D₃-specific DNA response element (VDRE) was shown to have high levels of activity in the cerebellum, an area of the brain that is frequently linked to ASD⁵⁶.

There is a striking relationship between neurotrophic factors, vitamin D₃, and autism. In a prospective study conducted with blood samples, neurotrophin levels from newborns with autism, mental retardation and cerebral palsy were compared with healthy control groups; a significant increase in neurotrophin-4 (NT-4) levels was detected in the subjects with autism and mental retardation, while no significant difference in neurotrophin-3 (NT-3) levels was found⁵⁷.

In a similar study by Miyazaki et al., subjects with autism and mental retardation were compared with a healthy control group, and it was determined that NT-4 levels were higher in subjects with mental retardation. Higher levels were also identified in autistic subjects, but no statistical significance was found⁵⁸. Nelson et al.

Table 2: Overlap between the Effects of Vitamin D and Autism in the Brain

Vitamin D ₃	References	Autism	References
Increases glutathione and has antioxidant effects on brain	Garcion et al., 1999; Ibi et al., 2001; Garcion et al., 1997	Deficits in glutathione redox systems	Rose et al., 2012; Gu et al., 2013
The regulation of proteins that regulate neuronal differentiation and changes at the cellular level, such as the regulation of cytokine and neurotrophin	Eyles et al., 2005; Féron et al., 2005; Eyles et al., 2003 Brown et al., 2003	In autism, micro-anatomical changes were also reported in the brain	Casanova et al., 2006
Changes in neurogenesis, apoptosis and mitosis	Ko et al., 2004; Féron et al., 2005; Brown et al., 2003		
Decreased iNOS	Garcion et al., 1997	NO increased	Sweeten et al., 2004;
No study		BDNF increased	Nelson et al., 2001; Miyazaki et al., 2004
Increased NGF mRNA	Neveu et al., 1994a;	No significant difference when compared to healthy control group	Nelson et al., 2001
Increased GDNF (mRNA)	Naveilhan et al., 1996	No study	
Increased NT-3 (mRNA)	Neveu et al., 1994a	NT-3 decreased	Nelson et al., 2006
Decreased NT-4 (mRNA)	Neveu et al., 1994a	NT-4 increased	Nelson et al., 2001
Vitamin D ₃ deficiency was held responsible for etiology of autoimmune disorder	Zhang et al., 2010; Hamza et al., 2011;	Autoimmune disorders are more common among the families of autistic patients	Sweeten et al., 2003

detected lower NT-3 levels in autistic patients compared to their healthy counterparts⁵⁹. In studies where NGF levels in autism, mental retardation and control groups were examined, no statistically significant differences were found between the groups⁵⁷. Several studies have found that vitamin D₃ increases NGF¹⁵ and GDNF²² levels.

In our study of patients diagnosed with autism and cognitive development disorders, we found a significant improvement in development scores and autistic symptoms and detected a significant increase in NGF levels, which suggests that NGF could be the prime mediator of vitamin D₃'s effects in patients with ASD²⁶. On the other hand, patients with cognitive developmental delay have been observed to have an increase in their GDNF that parallels the recovery of their developmental level, particularly in patients who have been given vitamin D₃ replacement therapy. It is thought provoking that there is a higher possibility of this effect taking place via GDNF in patients with cognitive developmental delays. Based on the

findings of the research, it was determined that NGF could be used to mark the progress of autistic disorders, and GDNF could be used to mark the progress of cognitive developmental deficits²⁶.

B. Immune System

The role of vitamin D₃ with respect to the immune system is frequently examined in the etiology of autism. Vitamin D₃ receptors have been detected in lymphocytes, activated B cells and dendritic cells⁶⁰. T cell dysfunctions have been revealed in autism⁶¹. Furthermore, an increasing number of studies has shown vitamin D₃ playing a role in allergic and autoimmune reactions⁶⁰. Recently, vitamin D₃ deficiency has been thought to be the trigger for some autoimmune disorders, such as multiple sclerosis and systemic lupus erythematosus⁶²⁻⁶⁴. Similarly, compared to the normal population, autoimmune disorders are more common among families who have children with autism spectrum disorder⁶².

A number of studies has been carried out solely on the vitamin D₃/autism/immunity relationship. In a study that examined the relationship between 25(OH)D₃ and anti-myelin-associated glycoprotein (anti-MAG) in autistic children, lower vitamin D₃ levels were detected compared to the healthy group and, as serum 25-hydroxyvitamin D₃ levels increased, autism symptoms decreased. Further, in nearly 70% of autistic patients, serum anti-MAG auto-antibodies levels were high; a negative correlation was detected between serum 25-hydroxyvitamin D₃ levels and anti-MAG auto-antibodies⁶².

C. Antioxidant Systems

Another area where vitamin D₃'s effects and the possible pathogenesis of autism overlap is in anti-oxidation systems. In several studies, autistic patients have been found to have deficits in their

glutathione redox systems, and this suggests that there could be a connection between systemic disorders and autism⁶⁵⁻⁶⁶. Accordingly, it has been determined that vitamin D₃ increases the quantity of antioxidant agents such as glutathione by increasing the enzyme gamma-glutamyl transpeptidase. This enzyme is responsible for glutathione formation in the physiologic formation of vitamin D₃, and thus plays a role in brain detoxification mechanisms²⁸.

Patients with ASD have also been found to have higher levels of nitric oxide compared to healthy control groups⁶⁸. Nitric oxide is a compound that is produced by iNOS, damaging neurons and oligodendrocytes when produced in high quantities⁶⁷. Vitamin D₃, on the other hand, has been shown to inhibit iNOS⁶⁹.

Figure 1 illustrates the possible mechanisms of how vitamin D₃ deficiency might form an 'autistic neuron'.




Figure 1: How vitamin D₃ deficiency might form an 'autistic' neuron

Conclusion and Future Directions

It has been shown that vitamin D₃ pathways in the brain might play a role in brain development and autism spectrum disorder pathophysiology. However, the scientific literature in this area has obtained its data based on animal studies, and current data do not seem to be sufficient to draw direct conclusions. Clinical studies need to be carried out to examine the relationship between vitamin D₃ and both brain development and autistic spectrum disorders. Focusing on oxidative stress, biological markers and neurotrophic factors

in these studies might generate significant data.

There is also a growing literature regarding the effect of vitamin A (retinol) on brain development and autism. A recent study has shown that CD38 gene transcription is reduced in subjects with autism, and this situation can be ameliorated by a simple treatment with all-trans retinoic acid⁷⁰. Considering the evidence showing the relationship between vitamin D₃ and vitamin A at a cellular level, future research should therefore concentrate on these two vitamins together when examining their effects on autism and brain development⁹.

References:

1. Valrance ME, Brunet AH, Welsh J. Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo. *Endocrinology* 2007;148(10):4887-94. [\[CrossRef\]](#)
2. Kennedy DA, Cooley K, Skidmore B, Fritz H, Campbell T, Seely D. Vitamin D: pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: a systematic review. *Cancers (Basel)* 2013;5(1):255-80. [\[CrossRef\]](#)
3. Ko P, Burkert R, McGrath J, Eyles D. Maternal vitamin D₃ deprivation and the regulation of apoptosis and cell cycle during rat brain development. *Brain Res Dev Brain Res* 2004;153(1):61-8. [\[CrossRef\]](#)
4. Féron F, Burne TH, Brown J, Smith E, McGrath JJ, Mackay-Sim A, et al. Developmental vitamin D₃ deficiency alters the adult rat brain. *Brain Res Bull* 2005;65(2):141-8. [\[CrossRef\]](#)
5. Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. *J Biol Chem* 2001;276(12):9101-7. [\[CrossRef\]](#)
6. Brown J, Bianco JJ, McGrath JJ, Eyles DW. 1,25-dihydroxyvitamin D₃ induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. *Neurosci. Lett* 2003;343(2):139-43. [\[CrossRef\]](#)
7. Pardridge WM, Sakiyama R, Coty WA. Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier. *J Neurochem* 1985;44(4):1138-41. [\[CrossRef\]](#)
8. Balabanova S, Richter HP, Antoniadis G, Homoki J, Kremmer N, Hanle J, et al. 25-hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. *Klin Wochenschr* 1984;62(22):1086-90. [\[CrossRef\]](#)
9. Eyles D, Burne T, McGrath J. Vitamin D in fetal brain development. *Semin Cell Dev Biol* 2011;22(6):629-36. [\[CrossRef\]](#)
10. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. *J Chem Neuroanat* 2005;29(1):21-30. [\[CrossRef\]](#)
11. Johnson JA, Grande JP, Windebank AJ, Kumar R. 1,25-Dihydroxyvitamin D(3) receptors in developing dorsal root ganglia of fetal rats. *Brain Res Dev Brain Res* 1996;92(1):120-4. [\[CrossRef\]](#)
12. Eyles D, Brown J, Mackay-Sim A, McGrath J, Feron F. Vitamin D₃ and brain development. *Neurosci* 2003(3):118:641-53. [\[CrossRef\]](#)
13. Cui X, McGrath JJ, Burne TH, Mackay-Sim A, Eyles DW. Maternal vitamin D depletion alters neurogenesis in the developing rat brain. *Int J Dev Neurosci* 2007;25(4):227-32. [\[CrossRef\]](#)
14. Eyles DW, Feron F, Cui X, Kesby JP, Harms LH, Ko P, et al. Developmental vitamin D deficiency causes abnormal brain development. *Psychoneuroendocrinology* 2009;34(Suppl.1):S247-S57. [\[CrossRef\]](#)
15. Neveu I, Naveilhan P, Baudet C, Brachet P, Metsis M. 1,25-dihydroxyvitamin D₃ regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. *Neuroreport* 1994;6(1):124-6. [\[CrossRef\]](#)
16. Saporito MS, Brown ER, Hartpence KC, Wilcox HM, Vaught JL, Carswell S. Chronic 1,25-dihydroxyvitamin D₃-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain. *Brain Res* 1994;633(1-2):189-96. [\[CrossRef\]](#)
17. Korsching S, Auburger G, Heumann R, Scott J, Thoenen H. Levels of nerve growth factor mRNA and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. *EMBO J* 1985;4(6):1389-93.
18. Xiong P, Zeng Y, Zhu Z, Tan D, Xu F, Lu J et al. Reduced NGF serum levels and abnormal P300 event-related potential in first episode schizophrenia. *Schizophr Res* 2010;119(1-3):34-9. [\[CrossRef\]](#)

19. Granholm AC, Reyland M, Albeck D, Sanders L, Gerhardt G, Hoernig G, et al. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. *J Neurosci* 2000;20(9):3182-90.
20. Quintero EM, Willis LM, Zaman V, Lee J, Boger HA, Tomac A, et al. Glial cell line-derived neurotrophic factor is essential for neuronal survival in the locus coeruleus-hippocampal noradrenergic pathway. *Neuroscience* 2004;124(1):137-46. [\[CrossRef\]](#)
21. Ma XC, Chen C, Zhu F, Jia W, Gao CG. Association of the GDNF gene with depression and heroin dependence, but not schizophrenia, in a Chinese population. *Psychiatry Res* 2013;210(3):1296-8. [\[CrossRef\]](#)
22. Naveilhan P, Neveu I, Wion D, Brachet P. 1,25-Dihydroxyvitamin D₃, an inducer of glial cell line-derived neurotrophic factor. *Neuroreport* 1996;7(13):2171-5. [\[CrossRef\]](#)
23. Mehta V, Hong M, Spears J, Mendez I. Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor. *J Neurosurg* 1998;88(6):1088-95. [\[CrossRef\]](#)
24. Michelato A, Bonvicini C, Ventriglia M, Scassellati C, Randazzo R, Bignotti S, et al. 3' UTR (AGG)_n repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. *Neurosci Lett* 2004;357(3):235-7. [\[CrossRef\]](#)
25. Ozkan B, Doneray H. The non-skeletal effects of vitamin D. *Çocuk Sağlığı ve Hastalıkları Dergisi* 2011;53(2):99-119. (Turkish)
26. Ucuz I, Dursun OB, Esin IS, Ozgeris FB, Kurt N, Kiziltunc A, et al. The relationship between Vitamin D, autistic spectrum disorders, and cognitive development: do glial cell line-derived neurotrophic factor and nerve growth factor play a role in this relationship? *Int J Dev Disabil. Epub* 2014. [\[CrossRef\]](#)
27. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. *Free Radic Biol Med* 2012;52(10):2128-41. [\[CrossRef\]](#)
28. Garcion E, Sindji L, Leblondel G, Brachet P, Darcy F. 1,25-dihydroxyvitamin D₃ regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. *J Neurochem* 1999;73(2):859-66. [\[CrossRef\]](#)
29. Wang Y, Chiang YH, Su TP, Hayashi T, Morales M, Hoffer BJ, et al. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. *Neuropharmacology* 2000;39(5):873-80. [\[CrossRef\]](#)
30. Ibi M, Sawada H, Nakanishi M, Kume T, Katsuki H, Kaneko S, et al. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. *Neuropharmacology* 2001;40(6):761-71. [\[CrossRef\]](#)
31. Wang JY, Wu JN, Cherng TL, Hoffer BJ, Chen HH, Borlongan CV, Wang Y. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. *Brain Res* 2001;904(1):67-75. [\[CrossRef\]](#)
32. Alexianu ME, Robbins E, Carswell S, Appel SH. 1 Alpha, 25 dihydroxyvitamin D₃-dependent up-regulation of calcium-binding proteins in motoneuron cells. *J Neurosci Res* 1998;51(1):58-66. [\[CrossRef\]](#)
33. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. *J Neurosci* 2001;21(1):98-108.
34. Cass WA, Smith MP, Peters LE. Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine. *Ann N Y Acad Sci* 2006;1074:261-71. [\[CrossRef\]](#)
35. Puchacz E, Stumpf WE, Stachowiak EK, Stachowiak MK. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. *Brain Res Mol Brain Res* 1996;36(1):193-6. [\[CrossRef\]](#)
36. Cui X, Pelekanos M, Burne TH, McGrath JJ, Eyles DW. Maternal vitamin D deficiency alters the expression of genes involved in dopamine specification in the developing rat mesencephalon. *Neurosci Lett* 2010;486(3):220-3. [\[CrossRef\]](#)
37. Kesby JP, Cui X, Ko P, McGrath JJ, Burne TH, Eyles DW. Developmental vitamin D deficiency alters dopamine turnover in neonatal rat forebrain. *Neurosci Lett* 2009;461(2):155-8. [\[CrossRef\]](#)
38. Doneray H. D Vitamini ve Beyin Dokusu. *Türkiye Klinikleri. J Pediatr Sci* 2012;8(2)100-3.
39. Cantorna MT, Mahon BD. D-hormone and the immune system. *J Rheumatol Suppl* 2005;76:S11-S20.
40. Garcion E, Sindji L, Montero-Menei C, Andre C, Brachet P, Darcy F. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D₃. *Glia* 1998;22(3):282-94. [\[CrossRef\]](#)
41. Nataf S, Garcion E, Darcy F, Chabannes D, Muller JY, Brachet P. 1,25 Dihydroxyvitamin D₃ exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. *J Neuropathol Exp Neurol* 1996;55(8):904-14. [\[CrossRef\]](#)
42. Carthy EP, Yamashita W, Hsu A, Ooi BS. 1,25-Dihydroxyvitamin D₃ and rat vascular smooth muscle cell growth. *Hypertension* 1989;13(6 Pt 2):954-9. [\[CrossRef\]](#)
43. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? *QJM* 2002;95(12):787-96. [\[CrossRef\]](#)
44. Kong XF, Zhu XH, Jackson DM, Holick MF. Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D₃-1alpha-hydroxylase gene. *Proc Natl Acad Sci U.S.A.* 1999;96(12):6988-93. [\[CrossRef\]](#)
45. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D₃: basic concepts. *J Steroid Biochem Mol Biol* 2005;97(1-2):93-101. [\[CrossRef\]](#)

46. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D₃ analogs as immunomodulatory agents. *Trends Mol Med* 2002;8(4):174-9. [\[CrossRef\]](#)
47. Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. *Clin Exp Immunol* 2000;120(1):139-46. [\[CrossRef\]](#)
48. Cannell JJ. Autism, will vitamin D treat core symptoms? *Med Hypotheses* 2013;81(2):195-8. [\[CrossRef\]](#)
49. Grant WB, Soles CM. Epidemiologic evidence supporting the role of maternal vitamin D deficiency as a risk factor for the development of infantile autism. *Dermatoendocrinol* 2009;1(4):223-8. [\[CrossRef\]](#)
50. Waldman M, Nicholson S, Adilov N, Williams J. Autism prevalence and precipitation rates in California, Oregon, and Washington counties. *Arch Pediatr Adolesc Med* 2008;162(11):1026-34. [\[CrossRef\]](#)
51. Meguid NA, Hashish AF, Anwar M, Sidhom G. Reduced serum levels of 25-hydroxy and 1,25-dihydroxy vitamin D in Egyptian children with autism. *J Altern Complement Med* 2010;16(6):6415. [\[CrossRef\]](#)
52. Molloy CA, Kalkwarf HJ, Manning-Courtney P, Mills JL, Hediger ML. Plasma 25(OH)D concentration in children with autism spectrum disorder. *Dev Med Child Neurol* 2010;52(10):969-71. [\[CrossRef\]](#)
53. Humble MB, Gustafsson S, Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric outpatients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. *J Steroid Biochem Mol Biol* 2010;121(1-2):467-70. [\[CrossRef\]](#)
54. Kočovská E, Fernell E, Billstedt E, Minnis H, Gillberg C. Vitamin D and autism: clinical review. *Res Dev Disabil* 2012;33(5):1541-50. [\[CrossRef\]](#)
55. Freitag CM, Staal W, Klauck SM, Duketis E, Waltes R. Genetics of autistic disorders: review and clinical implications. *Eur Child Adolesc Psychiatry* 2010;19(3):169-78. [\[CrossRef\]](#)
56. Taniura H, Ito M, Sanada N, Kuramoto N, Ohno Y, Nakamichi N, et al. Chronic vitamin D₃ treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. *J Neurosci Res* 2006;83(7):1179-89. [\[CrossRef\]](#)
57. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. *Ann Neurol* 2001;49(5):597-606. [\[CrossRef\]](#)
58. Miyazaki K, Narita N, Sakuta R, Miyahara T, Naruse H, Okado N, et al. Serum neurotrophin concentrations in autism and mental retardation: a pilot study. *Brain Dev* 2004;26(5):292-5. [\[CrossRef\]](#)
59. Nelson PG, Kuddo T, Song EY, Dambrosia JM, Kohler S, Satyanarayana G, et al. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. *Int J Dev Neurosci* 2006;24(1):73-80. [\[CrossRef\]](#)
60. Jones AP, Tulic MK, Rueter K, Prescott SL. Vitamin D and allergic disease: sunlight at the end of the tunnel? *Nutrients* 2012;4(1):13-28.
61. Cannell J. Autism and vitamin. *Med Hypotheses* 2008;70(4):750-9. [\[CrossRef\]](#)
62. Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. *J Neuroinflammation* 2012;9(1):201. [\[CrossRef\]](#)
63. Zhang HL, Wu J. Role of vitamin D in immune responses and autoimmune diseases, with emphasis on its role in multiple sclerosis. *Neurosci Bull* 2010;26(6):445-54. [\[CrossRef\]](#)
64. Hamza RT, Awwad KS, Ali MK, Hamed AI. Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. *Med Sci Monit* 2011;17(12):CR711-8. [\[CrossRef\]](#)
65. Rose S, Melnyk S, Trusty TA, Pavliv O, Seidel L, Li J, et al. Intracellular and extracellular redox status and free radical generation in primary immune cells from children with autism. *Autism Res Treat* 2012;2012:986519. [\[CrossRef\]](#)
66. Gu F, Chauhan V, Chauhan A. Impaired synthesis and antioxidant defense of glutathione in the cerebellum of autistic subjects: alterations in the activities and protein expression of glutathione-related enzymes. *Free Radic Biol Med* 2013;65:488-96. [\[CrossRef\]](#)
67. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. *Trends Endocrinol Metab* 2002;13(3):100-5. [\[CrossRef\]](#)
68. Sweeten TL, Posey DJ, Shankar S, McDougle CJ. High nitric oxide production in autistic disorder: a possible role for interferon-gamma. *Biol Psychiatry* 2004;55(4):434-7. [\[CrossRef\]](#)
69. Garcion E, Nataf S, Berod A, Darcy F, Brachet P. 1,25-Dihydroxyvitamin D₃ inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. *Brain Res Mol Brain Res* 1997;45(2):255-67. [\[CrossRef\]](#)
70. Riebold M, Mankuta D, Lerer E, Israel S, Zhong S, Nemanov L, et al. All-trans retinoic acid upregulates reduced CD38 transcription in lymphoblastoid cell lines from autism spectrum disorder. *Mol Med* 2011;17(7-8):799-806. [\[CrossRef\]](#)
71. Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. *Pediatrics* 2003;112(5):420-24. [\[CrossRef\]](#)
72. Casanova MF, van Kooten IA, Switala AE, van Engeland H, Heinsen H, Steinbusch HW, et al. Minicolumnar abnormalities in autism. *Acta Neuropathol* 2006;112(3):287-303. [\[CrossRef\]](#)